
    
      Eligible consenting patients will be randomly allocated to receive either the veno-device
      (active or placebo for 8 weeks and crossed over for a further 8 weeks (active or placebo)
      following a 4 week 'wash out' period.( A randomized controlled 'crossover' study}
    
  